Efficacy and safety of CagriSema & Retatrutide, CGM benefits beyond T2D, & more!
Welcome to the latest episode (July 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease.
This month on DOC Updates:
Aroda V, Buzzetti R, Dalskov S et al. "Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study." The Lancet Diabetes & Endocrinology, 2026; 0 doi: 10.1016/S2213-8587(26)00126-9
Bajaj H, Welch M, Shah P et al. "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." The Lancet, 2026; 407, 2402-2413 doi: 10.1016/S0140-6736(26)00967-0
Melville, N. "CGM Monitoring Benefits Extend to Non-Insulin-Using T2D." Medscape, June 07, 2026
Aronne, L.J., Horn, D.B., le Roux, C.W. et al. "Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial." Nat Med(2026) doi: 10.1038/s41591-026-04386-7
Salive ME, Tjaden AH, Ames JR, et al. "Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes." JAMA. Published online June 15, 2026. doi:10.1001/jama.2026.8492
Presented by:
Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health
For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update.
This month on DOC Updates:
Aroda V, Buzzetti R, Dalskov S et al. "Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study." The Lancet Diabetes & Endocrinology, 2026; 0 doi: 10.1016/S2213-8587(26)00126-9
Bajaj H, Welch M, Shah P et al. "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." The Lancet, 2026; 407, 2402-2413 doi: 10.1016/S0140-6736(26)00967-0
Melville, N. "CGM Monitoring Benefits Extend to Non-Insulin-Using T2D." Medscape, June 07, 2026
Aronne, L.J., Horn, D.B., le Roux, C.W. et al. "Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial." Nat Med(2026) doi: 10.1038/s41591-026-04386-7
Salive ME, Tjaden AH, Ames JR, et al. "Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes." JAMA. Published online June 15, 2026. doi:10.1001/jama.2026.8492
Presented by:
Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health
For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update.
Loading content...
Read the full transcript
Matterfact has every podcast on Apple Podcasts and Spotify: 700K+ channels, 120M+ episodes.
The candid version is on a podcast,
not the earnings call.
Matterfact turns the conversations your coverage is already having into a searchable, citable record — across every episode, not just this one.